RARE Quote, Financials, Valuation and Earnings

Amicus Therapeutics has a net margin of -108.46% compared to Ultragenyx Pharmaceutical's net margin of -17.31%. Ultragenyx Pharmaceutical's return on equity of -205.06% beat Amicus Therapeutics's return on equity of -17.7%.

Ultragenyx Pharmaceutical has a consensus price target of $89.84, signalling upside risk potential of 164.01%. On the other hand Amicus Therapeutics has an analysts' consensus of $15.82 which suggests that it could grow by 160.6%. Given that Ultragenyx Pharmaceutical has higher upside potential than Amicus Therapeutics, analysts believe Ultragenyx Pharmaceutical is more attractive than Amicus Therapeutics.

Ultragenyx Pharmaceutical has a beta of 0.337, which suggesting that the stock is 66.284% less volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.640, suggesting its less volatile than the S&P 500 by 35.979%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $139.3M, which are larger than Amicus Therapeutics quarterly revenues of $125.2M. Ultragenyx Pharmaceutical's net income of -$151.1M is lower than Amicus Therapeutics's net income of -$21.7M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 5.39x versus 3.42x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of -108.46% compared to Ultragenyx Pharmaceutical's net margin of -486.44%. Ultragenyx Pharmaceutical's return on equity of -205.06% beat Nektar Therapeutics's return on equity of -201.73%.

Ultragenyx Pharmaceutical has a consensus price target of $89.84, signalling upside risk potential of 164.01%. On the other hand Nektar Therapeutics has an analysts' consensus of $4.92 which suggests that it could grow by 578.63%. Given that Nektar Therapeutics has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Nektar Therapeutics is more attractive than Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical has a beta of 0.337, which suggesting that the stock is 66.284% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 0.623, suggesting its less volatile than the S&P 500 by 37.715%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $139.3M, which are larger than Nektar Therapeutics quarterly revenues of $10.5M. Ultragenyx Pharmaceutical's net income of -$151.1M is lower than Nektar Therapeutics's net income of -$50.9M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 5.39x versus 1.74x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -108.46% compared to Ultragenyx Pharmaceutical's net margin of 26.7%. Ultragenyx Pharmaceutical's return on equity of -205.06% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Ultragenyx Pharmaceutical has a consensus price target of $89.84, signalling upside risk potential of 164.01%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $763.80 which suggests that it could grow by 55.79%. Given that Ultragenyx Pharmaceutical has higher upside potential than Regeneron Pharmaceuticals, analysts believe Ultragenyx Pharmaceutical is more attractive than Regeneron Pharmaceuticals.

Ultragenyx Pharmaceutical has a beta of 0.337, which suggesting that the stock is 66.284% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.36% to investors and pays a quarterly dividend of $0.88 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $139.3M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Ultragenyx Pharmaceutical's net income of -$151.1M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 12.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 5.39x versus 3.97x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Xencor has a net margin of -108.46% compared to Ultragenyx Pharmaceutical's net margin of -147.92%. Ultragenyx Pharmaceutical's return on equity of -205.06% beat Xencor's return on equity of -32.34%.

Ultragenyx Pharmaceutical has a consensus price target of $89.84, signalling upside risk potential of 164.01%. On the other hand Xencor has an analysts' consensus of $28.20 which suggests that it could grow by 252.5%. Given that Xencor has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Xencor is more attractive than Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical has a beta of 0.337, which suggesting that the stock is 66.284% less volatile than S&P 500. In comparison Xencor has a beta of 0.992, suggesting its less volatile than the S&P 500 by 0.85%.

Ultragenyx Pharmaceutical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xencor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical pays -- of its earnings as a dividend. Xencor pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical quarterly revenues are $139.3M, which are larger than Xencor quarterly revenues of $32.7M. Ultragenyx Pharmaceutical's net income of -$151.1M is lower than Xencor's net income of -$48.4M. Notably, Ultragenyx Pharmaceutical's price-to-earnings ratio is -- while Xencor's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical is 5.39x versus 4.29x for Xencor. Usually stocks with elevated PS ratios are considered overvalued.